144 ·Filed Jun 11, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago SEC0001950047-26-005947
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The filing itself is routine and not directly actionable. Monitor for the executed Form 4 to confirm the sale actually occurred — the ~$1.44M amount is small relative to market cap and likely tax-motivated option exercise covering. No bearish read-through for RVMD from this isolated insider filing.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
RVMD ▲ +34.74% at T+60d
NEUTRAL call ✓ call won +34.74% · α vs SPY +31.47% · entry $153.87 → $207.32
Entry anchored
Jun 11, 03:59 PM ET
via exchange tick
T+1d
+4.02%
call +4.02% · α +2.26%
$160.06
settled 4mo ago
T+5d
+5.93%
call +5.93% · α +5.25%
$162.99
settled 4mo ago
T+20d
+21.45%
call +21.45% · α +19.67%
$186.88
settled 3mo ago
T+60d
+34.74%
call +34.74% · α +31.47%
$207.32
settled 24d ago

Price Chart

Loading chart...

Executive Summary

Director Margaret A. Horn files Form 144 notice of intent to sell 10,000 shares (~$1.44M based on stated value). This is a relatively modest sale relative to the $30.7B market cap, representing ~0.00003% of shares outstanding. The shares are being sold to cover option exercise costs, a routine insider transaction pattern.

Key Facts

  • Director Margaret A. Horn filed Form 144 on 2026-06-11
  • Proposed sale of 10,000 shares with approximate value of $1,441,900
  • Shares to be sold through Morgan Stanley Smith Barney LLC
  • Sale is to cover costs of exercising stock options (cash exercise)
  • Horn not a named executive officer — holds board director role

Financial Impact

~$1.44M proposed sale value; director ownership stake undisclosed but likely moderate at ~$30.7B market cap

no change to core financials

Risk Factors

  • Insider may be incrementally reducing exposure ahead of any near-term clinical data readout
  • Form 144 is intent-to-sell only; sale may not execute if conditions change

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005947
Document: 0001950047-26-005947-index.html0001950047-26-005947
Document: 0001950047-26-005947.txt0001950047-26-005947
26 reports for RVMD
Performance horizon
100% Hit rate 12 of 12 directional calls best @ T+60▲ +31.56%Apr 21, 2026
Filters
Rows
Reports for RVMD — sortable, filterable
TypeNow
Sep 15, 2026
16d ago
144
NEUTRAL ★ 2/10
$195.92 $190.74▼ −2.64%▼ −5.21%$206.68 (+5.49%)
Sep 15, 2026
16d ago
144
NEUTRAL ★ 4/10
$195.92 $190.74▼ −2.64%▼ −5.21%$206.68 (+5.49%)
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$204.86 $190.95▼ −6.79%▼ −7.61%$206.68 (+0.89%)
Sep 14, 2026
17d ago
Insider Cluster
NEUTRAL ★ 3/10
$204.86 $192.86▼ −5.86%▼ −7.98%$206.68 (+0.89%)
Aug 26, 2026
5w ago
8-K
BULLISH ★ 8/10
$215.44 $209.23▼ −2.88%▼ −2.76%$206.68 (−4.06%)
Aug 26, 2026
5w ago
Press Release
BULLISH ★ 8/10
$215.44 $209.23▼ −2.88%▼ −2.76%$206.68 (−4.06%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$211.38 $209.87▼ −0.71%▼ −0.18%$206.68 (−2.22%)
Jul 2, 2026
13w ago
Press Release
BULLISH ★ 7/10
$189.24 $191.13▲ +1.00%▲ +0.07%$206.68 (+9.22%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$187.51 $190.46▲ +1.57%▲ +1.31%$206.68 (+10.23%)
Jun 22, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$165.81 $192.62▲ +16.17%▲ +16.62%$206.68 (+24.65%)
Showing 10 of 26

US Market Status

Market Open — Closes in 2h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access